Vital Therapies Announces Fourth Quarter and Full Year 2014 Financial Results and Provides a Corporate Update
19 mars 2015 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, March 19, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute liver failure,...
Vital Therapies Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call With Webcast
05 mars 2015 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, March 5, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, will...
Vital Therapies Announces VTI-208 Phase 3 Clinical Trial Reaches Enrollment Target
30 janv. 2015 08h00 HE
|
Vital Therapies, Inc.
- ON TRACK FOR RELEASE OF TOPLINE DATA IN THE SECOND QUARTER OF 2015 -
- 200 PATIENTS ENROLLED -
SAN DIEGO, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a...
Vital Therapies Provides Clinical and Regulatory Update
12 janv. 2015 08h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, today...
Vital Therapies Announces First Subject Enrolled in VTI-210 and Provides Update on Enrollment in VTI-208
08 déc. 2014 08h00 HE
|
Vital Therapies, Inc.
SAN DIEGO, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, today...
Vital Therapies Expands Management Team
20 nov. 2014 08h00 HE
|
Vital Therapies, Inc.
SAN DIEGO, Nov. 20, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure,...
Vital Therapies Announces Third Quarter 2014 Financial Results and Provides a Corporate Update
13 nov. 2014 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Nov. 13, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, today...
Vital Therapies Announces Third Quarter 2014 Financial Results Conference Call With Webcast and Upcoming Conference Presentation
30 oct. 2014 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, will...
Vital Therapies Announces Pricing of Follow-On Offering
02 oct. 2014 22h00 HE
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 2, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute liver failure,...
Vital Therapies Announces Launch of Proposed Follow-On Offering
30 sept. 2014 16h08 HE
|
Vital Therapies, Inc.
SAN DIEGO, Sept. 30, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute liver failure,...